Sutro Biopharma appoints Vice President of Alliance and Project Management

Nicki Vasquez brings expertise in management of preclinical and clinical therapeutic development to the firm

Sutro Biopharma, a privately owned biotechnology company located in South San Francisco, US, has appointed Nicki Vasquez as Vice President of Alliance and Project Management.

Vasquez takes a leadership role in the management of Sutro's collaborative partnerships and the development of its antibody-drug conjugates, bispecific antibodies and antibody-based therapeutics targeting immuno-oncology pathways.

Vasquez brings more than 22 years of experience in the biopharmaceutical sector with expertise in management of preclinical and clinical therapeutic development; as well as expertise in research operations and programme management. Most recently, she was Vice President of Programme and Portfolio Management at StemCells, where she was responsible for building and driving forward R&D programme management for the company's preclinical and leading Phase II programmes.

Prior to StemCells, Dr Vasquez held several senior positions at Elan (now acquired by Perrigo).

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now